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1. Introduction
1.1. Treatment for ischemic heart diseases: State-of-the-art
Cardiovascular diseases, especially ischemic heart disease, are the leading cause of mortality
in the United States [1]. In the past decades, pharmacological therapy, such as β-blocker,
Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker(ARB) have
been shown to ameliorate cardiac dysfunction and limit heart remodeling following myocar‐
dial infarction [2]. Moreover, the development of coronary artery bypass graft (CABG) can
recanalize occlusive coronary and salvage the remaining surviving myocardium [3]. More
recently, with the development of percutaneous coronary intervention (PCI), retrograde
approach through collaterals has been introduced for percutaneous recanalization of chronic
total occlusion (CTO) of the coronary arteries, a new option for the patient with CTO beyond
CABG [4]. Unfortunately, even with great advances of these modern technologies, myocardial
infarctions will eventually develop into decompensated chronic heart failure. Heart trans‐
plantation is currently the last resort for the patient with end-stage heart failure. However, this
therapeutic option is limited by donor organ shortage and eventual organ rejection [5].
Therefore, new therapies are required to prevent the progression of pathological remodeling
and cell death, as well as to induce tissue recovery in the ischemic heart. Regenerative
cardiovascular medicine becomes a holy grail with the goal to replace and repair the damaged
myocardium and reverse heart dysfunction. In the past two decades, a variety of stem cells
have been investigated by scientists to achieve this goal [6]. Recently developed reprogram‐
ming technology, induced pluripotent stem cells (iPSC) has become an alternative source for
embryonic stem cells (ESC) without the ethical drawbacks [7], showing their powerful
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potential to differentiate into desired cell type [8]. A new discipline termed stem cell engi‐
neering has recently emerged aiming to reconstruct the damaged heart by integrating
progenitor/stem cell biology and bioengineering technology [9]. In this chapter, the recent the
recent advances and challenges of progenitor/stem cell engineering for the therapy of ischemic
heart disease will be discussed from a translational perspective.
2. Proper cell sources
Appropriate cell sources for stem cell engineering must meet the following requirements: 1)
The cell must be electromechanically coupled with the host heart tissue. 2) They must survive
in the hostile environment created by ischemic stress [10]. In this regard, several cell types have
been tried. Skeletal myoblast was the pioneering attempt but it was found to be limited to
contract synchronously with the host myocardium [11]. Bone marrow derived stem cells or
hematopoietic stem cells are easily obtained in clinical setting but their potential of cardiogenic
differentiation is still being debated [10]. The recent discovery of multipotent cardiac progen‐
itors have been proven to give rise to cardiomyocytes, endothelial, and smooth muscle cells,
forming the basic “components” for heart reconstruction [12]. The attempt to discover
endogenous cardiac progenitors showed some of those express c-Kit [13, 14] or Sca-1 [14]
markers. Transplantation of c-Kit+ cell resulted in neovascularization and cardiomyogenesis
in the infarcted heart [13]. Moreover, the cardiosphere obtained from human heart tissue
contained a mixed population of c-Kit+ and Sca-1+ cells and could regenerate infarcted heart
[15]. These encouraging results led to the initiation of several phase 1 clinical trials: ALCADIA
((AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy,
NCT00981006), SCIPIO (Cardiac Stem Cell Infusion in Patients with Ischemic Cardiomyop‐
athy) (NCT00474461), and CADUCEUS (NCT00893360). Preliminary data from the SCIPIO
and CADUCEUS (CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar
dysfunction) trials have been recently published in the Lancet [16, 17]. Both studies were aimed
to evaluate the feasibility and safety of intracoronary injection of autologous heart-derived
cells in a patient post myocardial infarction. The SCIPIO study [16] used c-kit+ cells that were
cultured from atrial tissue, whereas the CADUCEUS study [17] is using cardiospheres cultured
from biopsy-obtained right ventricular tissue. There is no report related to severe side effect
associated with cardiac cell injection in these two studies, although more adverse events were
observed in CADUCEUS study (treatment group). Both studies reported reduction in infarct
size following cell injection, but only the SCIPIO trial reported an improvement in left
ventricular ejection fraction (LVEF). There are still some limitations in these results, as
indicated by the limited sample size (16 in SCIPIO and 17 in CADUCEUS) and the absence of
a placebo group. Therefore, phase 2 study must be initiated in the future to further confirm its
safety and efficacy.
Furthermore, stimulation of the adult progenitor pool with epicardial origin after an acute
myocardial infarction (AMI) has been reported with some progress [18-20].  The success‐
ful  production  of  iPSC  by  transducing  pluripotent-regulated  transcriptional  factors  has
made it a powerful weapon for ex vivo expansion of cardiomyocytes [21]. And the direct
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differentiation of pluripotent stem cells can be enhanced by administration of BMP4 and
activin A [22, 23]. How to remove undifferentiated stem cells from differentiated cardio‐
myocytes  has  been a  major  challenge in  translational  cardiovascular  medicine.  Potential
solutions to this problem might be can be overcome by i) purification of isl-1+ ventricular
precursors  followed  by  committed  differentiation  [24]  or  ii)  transgenic  enrichment  via
negative  selection  of  iPSC using  a  suicide  gene  (thymidine  kinase)/positive  selection  of
cardiomyocytes  expressing a  bicistronic  reporter  GFP expression under  control  of  alpha
myosin heavy chain promoter [25]. Taken together, these cells provide a valuable source
for  generation  of  a  cell  sheet/patch  for  tissue  engineering  purpose.  Therefore,  there  are
two techniques commonly used for cardiac repair. The first is transplantation of stem cells
with  cardiogenic  potential  into  injured heart  or  pre-induction  of  stem cells  into  cardio‐
myocytes followed by implantation. The second is stimulation of the endogenous cardiac
progenitor pool to propagate cardiovascular offspring. More recently,  the laboratories of
Deepak Srivastava and Eric  Olson reported a  new method,  termed by “in  vivo reprog‐
ramming  of  cardiomyocytes”,  making  in  vivo  transformation  of  scar  tissue  into  beating
heart muscle possible. By transducing with retroviruses encoding GMT (GATA4, MEF2C,
TBX5) [26] or GMTH (GMT+Hand2) [27] in vivo following left anterior descending artery
(LAD) ligation, cardiac fibroblasts,  the natural “partner” of cardiomyocytes, become acti‐
vated, migrate to the injured site, and proliferate, thus rendering these cells susceptible to
retroviral infection and subsequent epigenetic reprogramming event. Both groups report‐
ed a significant conversion of transduced fibroblasts, identified by genetic lineage tracing
of  non-cardiomyocyte  in  the  heart,  to  an  ‘‘induced  cardiomyocyte-like  (iCM)’’  or  ‘‘in‐
duced  cardiac-like  myocyte  (iCLM)’’  state  iCMs/iCLMs.  Although  without  presence  of
rhythm disorder  in  mice,  it  is  necessary  to  test  the  approach in  pigs,  whose  hearts  are
similar to those of human in terms of size and physiology, to further evaluate its efficacy
and safety before clinical trial.
3. Engineering approach
Direct injection of cell suspension into infarcted area or peri-infarcted area is still the main
progenitor/stem cell treatment used for cardiac repair. Nevertheless, the poor survival of stem
cells in the harsh environment (hypoxia, inflammatory cytokines, etc.) limits the reparative
function of progenitor/stem cells in ischemic heart [28].
Combining progenitor/stem cell biology and bioengineering, tissue engineering holds great
promise to generate viable three dimensional heart tissue with vasculature prior to engraftment
to the heart, as an integral part of the host. This tissue graft should display contractile and elec‐
tromechanical coupled properties, contributing to the improvement of heart function. The re‐
cent evidence from large animals indicated that human ES-derived cardiomyocytes electrically
coupled and suppressed arrhythmias in injured hearts. This provided support for the contin‐
ued development of human stem cell derived tissue graft for cardiac repair [29]. The conven‐
tional approach involved seeding cell on scaffolds and culture in vitro prior to implantation.
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Eschenhagen and Zimmermann constructed an engineering heart tissue (EHT) by seeding
neonatal rat cardiomyocytes and a mix of collagen I, extracellular matrix proteins (Matrigel)
into a lattices or circular molds. Upon spontaneous remodeling of the liquid reconstitution
mixture and cyclic mechanical, EHT spontaneously and synchronously contracted after one
to two weeks of cultivation, which highlights the great importance of physical stimulation on
the maintenance of the physical and mechanical function of EHT [30]. This pioneering work
for the first time showed EHT could ameliorate cardiac function post MI.
3.1. Scaffold free tissue construct
The use of cell sheets provides a simple scaffold-free approach by seeding cardiac cells on poly
(N-isopropylacrylamide)-grafted polystyrene dishes and then lowering the temperature to
20ºC, thus inducing the detachment of intact cell monolayers without enzymatic digestion.
Using this method, a 1-mm-thick cell patch can be created by serial stacking of multiple
monolayer sheets [31]. A recent study by Murry group using ESC-derived cardiomyocytes
reported another scaffold free approach, demonstrating cell aggregation is sufficient to
generate functional EHT also showing endothelial cell and fibroblast are required for the
survival and integration of EHT and in host myocardium [32]. Further studies are needed to
optimize the proportion of cardiomyocyte, endothelial cells, and fibroblast for maximal
performance of EHT.
3.2. Construction of myocardial tissue/heart using decellularized native tissue
In order to create decellularized scaffolds, Taylor and her team perfused rat hearts with
detergents to remove the cells and leave a complex architecture of acellular extracellular
matrix  (ECM) behind.  [33].  This  native  scaffold  was  reseeded with  cardiomyocytes  and
endothelial cells taken from rats. They then placed these constructs in bioreactors that si‐
mulated blood pressure, electrical stimulation, and other aspects of cardiac physiology to
assure  integration of  the  scaffold and seeded cells.  Although approximately  only 2% of
normal contractile activity was acquired from this approach, this is a successful proof-of-
concept trial and might be the ultimate biomimetic method for constructing an intact hu‐
man heart.
3.3. Porous scaffolds
By using electrical stimulation, Vunjak-Novakovic et al., established a method to assemble
individual cardiomyocytes into a functional cell patch [34]. The hydrogel-encapsulated
neonatal rat heart cells were cultivated on porous collagen scaffolds. Currently, this method‐
ology has been applied in other cell types (e.g. hESC) [35] and with other scaffold material (e.g.
synthetic elastomers) [36]. 3 days before electrical stimulation, the cells were cultured in petri
dishes to allow sufficient expression of gap junction protein (e.g. Cx43) and other molecules
involved in contraction. Then the cells were subjected to electrical stimulation to induce
synchronous contraction and alteration of structural organization, resulting in the formation
of mature myocardium with elongated, viable cells aligned in parallel.
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3.4. Biological and synthetic polymers
Collagen is the first biological polymer used for fabrication of three dimensional tissues. It was
reported that neonatal rat cardiomyocytes spontaneously contracted when cultivated in
gelatin coated scaffold. Although the implanted cardiomyocytes survived in infarcted heart,
LVEF is not significantly improved after long term observation. Furthermore, Zimmermann’s
group engineered contractile 3-D heart tissue, in which cardiomyocytes encapsulated with
ring--shaped hydrogels (collagen and Matrigel) showing reduction of ventricle dilatation,
significant ventricular wall thickening and improvement of the fractional shortening (FS) [30].
The improvement of cardiac function, myofibril organization indicated that mechanical
stimulation is important for maturation of myocardial structure. Leor et al. also reported that
3-D alginate scaffolds seeded with fetal rat cardiomyocytes attenuated left ventricular
dilatation and deterioration of the heart function after myocardial infarction [37].
4. Progenitor/stem cell niche engineering
As we discussed above, the laboratories of Deepak Srivastava and Eric Olson were successful
in reprogramming cardiac fibroblasts in vivo into cardiomyocytes with a significant efficiency.
In 2010, Deepak’s team attempted to reprogram cardiac fibroblast into cardiomyocytes with
the same combination of transcription factors in vitro but experienced low efficiency [38], while
recently Sean M. Wu’s team reported in some cases, the reprogramming is still inefficiency
[39]. The great difference with respect to reprogramming efficiency in vitro and in vivo using
the same transcription factor cocktail suggested that the local microenvironment (niche) is a
critical checkpoint for cell reprogramming and regeneration. In vivo, the stem cell niche is a
complex and dynamic unit, and how these components interact to modulate progenitor/stem
cell fate is on the horizon to be understood. Alteration of the properties of progenitor/stem cell
niches may provide new therapeutic strategies for progenitor/stem cell engineering by
interrupting cardiac remodeling or accelerating the reparative process. Here we discuss two
key expects of progenitor/stem cell niche, namely mechanical cue and chemical cues and their
implication for progenitor/stem cell engineering.
4.1. Matrix rigidity
Progenitor/stem cell engineering involves coordination of selective proliferation of precursor/
stem cells and differentiation into target somatic cells (cardiomyocytes, smooth muscle cell,
and endothelial cells). Mechanical cues influence proliferation, differentiation, migration, and
spatial morphological organization. These cues include the rigidity of the surrounding matrix
or cell adhesion substratum. Thus, better understanding of the role of matrix rigidity is critical
for optimization of the regimes of mechanical conditioning of cultured tissue constructs. Based
on a pioneering study which discovered mechanosensitive transcriptional mechanism in 2009
[40], Kshitiz et al showed that resident cardiac progenitor cells continually monitored cell
substratum rigidity and demonstrated enhanced proliferation, endothelial differentiation, and
morphogenesis when the cell substratum rigidity closely matched that of myocardium [41].
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This process is mediated by p190RhoGAP, a guanosine triphosphatase–activating protein for
RhoA, acting through RhoA-dependent and -independent mechanisms. Downregulation of
p190RhoGAP triggered a series of developmental events by coupling cell-cell and cell-
substratum interactions to genetic circuits controlling differentiation. Hence, preconditioning
of endothelial progenitors could change p190RhoGAP abundance and thus promote angio‐
genesis in engrafted heart. More generally, the results suggest the importance of the feedback
between the rigidity of a developing or regenerating tissue and the control of cell growth and
differentiation, which may be critical for adaptive development and maintenance of structur‐
ally complex tissues and organs.
Figure 1. Fabrication of “Super Cell Patch”. Progenitor/cells were treated with exosome containing microRNAs
(miRs), growth factors (GFs) and cytokines etc. Then the progenitor/stem cells were administered with optimized ECM
to provide the suitable matrix rigidity for engraftment. Subsequently, confluent cells forming sheets were released
from the dish surface by decreasing temperature from 37ºC to 20ºC. Then, several cell sheets were stratified and




Recent studies have suggested four potential mechanisms for how exogenous-culture-
expanded MSC may contribute to cardiovascular repair: transdifferentiation, cell fusion with
a native cell, stimulation of endogenous cardiac progenitor/stem cells via direct cell-cell
communication or paracrine mechanism [42]. Transdifferentiation of MSC into cardiomyo‐
cytes is not inefficient in current regimes [10]. Cell fusion is a rare event[43]. As aforemen‐
tioned, the observed salutary effects of progenitor/stem cell on cardiac repair probably resulted
from paracrine mechanism. And the cardiogenic differentiation of CSC stimulated by MSC
processed a limited capacity [44]. By antibody array and Liquid Chromatography with
Tandem Mass Spectrometry Detection (LC-MS/MS), compelling evidences have shown MSC
could secrete a wide spectrum of trophic proteins that could induce proliferation and differ‐
entiation of CPC and angiogenesis [45]. Interestingly, in 2007, the paper published on Nature
Cell Biology revealed mRNAs and microRNAs in the exosome (the major microvesicle for
intercellular communication) can be delivered from one cell to another, and can be functional
in this new location [46]. This hallmark study elicited amazing expansion of studies on
exosomes in the last 3 years, making it a very exciting field now. A recent study has targeted
exosomes to the brain to treat Alzheimer's disease by engineering exosomes with dendrite cells
marker [47]. This study highlighted the possibility that cardiac-specific exosomes can be
engineered to treat ischemic heart diseases without any risk of immunorejection or carcino‐
genesis by viral infection. Thus, compared to the delivery of single growth factors or cytokines,
the direct administration of exosomes derived from preconditioned progenitors/stem cells into
ischemic heart or using cell sheet/patch modified with preconditioned exosomes might be a
new trend to improve cardiac repair in a more efficient way (Fig. 1).
5. Conclusions
Progenitor/stem cell engineering has presented as an exciting and promising avenue for the
treatment of ischemic heart diseases. Regeneration of damaged heart by progenitor/stem cell
engineering is becoming a fact rather than fiction. The translation of experimental discovery
in progenitor/stem cell engineering into clinical application should be accelerated and large
scale clinical trials should be initiated in the patients with ischemic heart diseases. Therefore,
the collaboration of progenitor/stem cell biologists, bioengineers, and physicians is possibly
the future modality in personalized regenerative medicine.
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